Cargando…
The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers
The pharmacokinetics, pharmacodynamics, safety, and tolerability of BMS-932481, a γ-secretase modulator (GSM), were tested in healthy young and elderly volunteers after single and multiple doses. BMS-932481 was orally absorbed, showed dose proportionality after a single dose administration, and had...
Autores principales: | Soares, Holly D., Gasior, Maciej, Toyn, Jeremy H., Wang, Jun-Sheng, Hong, Quan, Berisha, Flora, Furlong, Michael T., Raybon, Joseph, Lentz, Kimberley A., Sweeney, Francis, Zheng, Naiyu, Akinsanya, Billy, Berman, Robert M., Thompson, Lorin A., Olson, Richard E., Morrison, John, Drexler, Dieter M., Macor, John E., Albright, Charlie F., Ahlijanian, Michael K., AbuTarif, Malaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931877/ https://www.ncbi.nlm.nih.gov/pubmed/27189973 http://dx.doi.org/10.1124/jpet.116.232256 |
Ejemplares similares
-
Identification and Preclinical Evaluation of the Bicyclic
Pyrimidine γ-Secretase Modulator BMS-932481
por: Boy, Kenneth M., et al.
Publicado: (2019) -
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
por: Toyn, Jeremy H., et al.
Publicado: (2016) -
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
por: Toyn, Jeremy H., et al.
Publicado: (2014) -
Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017) -
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
por: Toyn, Jeremy H, et al.
Publicado: (2014)